Sangamo Therapeutics, Inc.
SGMO
$0.6223
-$0.0309-4.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -67.20% | -74.04% | -94.38% | -92.22% | 58.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -67.20% | -74.04% | -94.38% | -92.22% | 58.34% |
| Cost of Revenue | -51.61% | -43.53% | -33.75% | -20.43% | -7.78% |
| Gross Profit | 0.93% | -95.13% | -341.76% | -1,260.80% | 60.88% |
| SG&A Expenses | -25.70% | -24.09% | -18.74% | -18.98% | -4.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.25% | -39.55% | -30.67% | -20.13% | -7.06% |
| Operating Income | 13.95% | -25.00% | -107.28% | -198.65% | 43.22% |
| Income Before Tax | 62.68% | 46.92% | -21.65% | -163.20% | -37.04% |
| Income Tax Expenses | 96.71% | 99.74% | 120.24% | -1,014.69% | -1,282.28% |
| Earnings from Continuing Operations | 62.01% | 45.96% | -25.78% | -157.97% | -34.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.01% | 45.96% | -25.78% | -157.97% | -34.09% |
| EBIT | 13.95% | -25.00% | -107.28% | -198.65% | 43.22% |
| EBITDA | 6.03% | -41.51% | -129.57% | -236.37% | 47.55% |
| EPS Basic | 65.09% | 48.60% | -15.81% | -127.01% | -17.27% |
| Normalized Basic EPS | 15.06% | -31.69% | -101.35% | -174.37% | 54.54% |
| EPS Diluted | 64.61% | 48.67% | -14.71% | -123.66% | -17.14% |
| Normalized Diluted EPS | 15.01% | -31.58% | -100.70% | -173.34% | 54.40% |
| Average Basic Shares Outstanding | 15.07% | 12.49% | 11.04% | 10.95% | 13.05% |
| Average Diluted Shares Outstanding | 15.82% | 13.25% | 10.93% | 10.84% | 13.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
